Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Infect Immun ; 68(4): 1796-805, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10722566

ABSTRACT

Systemic immunization with antigen coupled to monoclonal antibody (MAb) has been used by several investigators to increase the number of MAb-producing hybridomas against an antigen and to elicit antibodies specific for poorly immunogenic epitopes. This strategy has implications for vaccine design in that protective immunity is not necessarily directed at immunodominant epitopes of pathogens and may be improved by deliberately shifting the immune response toward subdominant epitopes. To our knowledge, no studies to date have addressed the potential for immunomodulatory activity mediated by MAbs bound to mucosally applied antigen. To test whether administration of an exogenous MAb directed against a streptococcal surface protein could influence the humoral immune response, BALB/c mice were immunized orally by gastric intubation or intranasally with Streptococcus mutans alone or S. mutans complexed with a MAb directed against the major surface protein P1. Significant changes in the subclass distribution, as well as the specificity, of anti-P1 serum immunoglobulin G antibodies were demonstrated in groups of mice which received S. mutans coated with the anti-P1 MAb versus those which received S. mutans alone. Alterations in the humoral immune response were dependent on the amount of anti-P1 MAb used to coat the bacteria. In addition, differences in the anti-P1 immune responses were observed between groups of mice immunized via oral versus intranasal routes. In summary, an exogenous MAb complexed with a streptococcal antigen prior to mucosal immunization can influence the immunoglobulin isotype and specificity of the host humoral immune response against the antigen.


Subject(s)
Antibodies, Bacterial/biosynthesis , Antibodies, Monoclonal/immunology , Antigens, Bacterial/immunology , Mouth Mucosa/immunology , Streptococcus mutans/immunology , Administration, Intranasal , Administration, Oral , Animals , Antibody Specificity , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , Immunization , Immunoglobulin G/blood , Immunoglobulin G/immunology , Mice , Mice, Inbred BALB C , Saliva/immunology , Vagina/immunology
3.
J Periodontol ; 69(4): 479-84, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9609379

ABSTRACT

Previous studies have shown epidermal growth factor (EGF) to be involved in oral wound healing as well as gastric cytoprotection. EGF functions with hormone-like properties to stimulate epithelial cells by binding to the EGF receptor which ultimately leads to proliferation via signal transduction mechanisms. Salivary glands are a major source of EGF The purpose of this study was to determine if intra-oral wounding by periodontal surgery stimulated increased salivary EGF levels. Salivary EGF levels were determined for 12 systemically healthy individuals (ages 27 to 70 years old) presurgically and postsurgically at 6, 12, 18, 24, 30, 36, and 42 hours and 2 and 6 weeks. Three ml of unstimulated whole saliva was obtained at each time point to allow immunoassay quantitation. Age and gender matched unoperated patients served as controls. Salivary samples were incubated with monoclonal and polyclonal EGF antibodies in these "sandwich" enzyme immunoassays. Quantitation was obtained by spectrometric analysis at OD 450 nm after addition of 200 microl of colorimetric substrate. Mean EGF levels ranged from 2441 pg/ml presurgically to 3349 pg/ml at 18 hours postsurgically and 1207 pg/ml at 6 weeks postsurgically. Repeated measures analysis of variance indicated statistically significant differences in 18 hours postsurgical salivary EGF levels when compared to controls and to postsurgical levels from 36 hours forward (P < 0.01). A second smaller rise in EGF was detected at 30 hours. These results suggest a transient increase in salivary EGF levels in response to intra-oral wounding.


Subject(s)
Alveolar Bone Loss/surgery , Epidermal Growth Factor/biosynthesis , Salivary Proteins and Peptides/biosynthesis , Wound Healing/physiology , Adult , Aged , Analysis of Variance , Case-Control Studies , Female , Humans , Immunoenzyme Techniques , Male , Middle Aged
4.
Clin Exp Rheumatol ; 15(5): 515-21, 1997.
Article in English | MEDLINE | ID: mdl-9307859

ABSTRACT

OBJECTIVE: Bromhexine has been reported to alleviate the xerostomia and xerophthalmia associated with secondary Sjögren's syndrome. The aim of this study was to determine if it might prove useful in the treatment of Sjögren's syndrome-like disease of the NOD mouse model for autoimmune sialoadenitis. METHODS: Groups of mice were divided into sets receiving 60 mg/kg bromhexine in drinking water and control pair-fed animals. The efficacy of drug treatment was assessed by weekly measurement of stimulated saliva volumes, protein concentration, and amylase activity. At termination (20 weeks) submandibular and lacrimal glands were removed to assess the levels of lymphocytic infiltration by histological evaluation under light microscopy. RESULTS: Control and bromhexine-treated groups of mice showed no difference in the loss or rate of reduction in stimulated saliva flow over the 12 weeks of treatment. No differences were noted in the protein concentration and amylase loss with increasing age of the animals. Similar temporal changes in total protein profiles and aberrant expression of the 20 kDa parotid secretory protein isoform were observed by SDS-polyacrylamide gel profiles and Western bolt analysis. Histological evaluation of exocrine gland sections failed to detect any reduction in focal lymphocyte infiltration. CONCLUSION: Bromhexine therapy did not alter the development or severity of Sjögren's syndrome-like disease in the NOD mouse model for autoimmune sialoadenitis.


Subject(s)
Bromhexine/pharmacology , Expectorants/pharmacology , Sjogren's Syndrome/drug therapy , Amylases/metabolism , Animals , Blotting, Western , Disease Models, Animal , Lacrimal Apparatus/metabolism , Lacrimal Apparatus/pathology , Lymphocytes , Male , Mice , Mice, Inbred NOD , Saliva/chemistry , Saliva/enzymology , Saliva/metabolism , Salivary Glands/metabolism , Salivary Glands/pathology , Salivary Proteins and Peptides/analysis , Salivary Proteins and Peptides/metabolism
5.
Proc Natl Acad Sci U S A ; 94(11): 5767-71, 1997 May 27.
Article in English | MEDLINE | ID: mdl-9159148

ABSTRACT

Nonobese diabetic (NOD) mice develop an anti-exocrine gland pathology similar to human Sjögren syndrome. Recently, we demonstrated that NOD-scid mice develop severe loss of submandibular acinar cells with concomitant appearance of abnormal isoforms of salivary proteins suggesting de novo enzymatic cleavage. Because these changes may indicate activation of apoptotic proteases, we examined saliva and salivary tissue for cysteine protease activity. Cysteine protease activities were elevated in saliva and gland lysates from 20-week-old NOD and NOD-scid mice as compared with age- and sex-matched BALB/c or 8-week-old NOD mice. This activity appeared in the submandibular glands, but not in the parotid glands. Western blot analyses using antibodies directed against specific apoptotic proteases (interleukin 1beta converting enzyme, Nedd-2, and Apopain/CPP 32) confirmed these findings. Submandibular glands from NOD-scid mice exhibited the greatest increase in proteolytic activity, indicating that infiltrating leukocytes are not responsible for these changes. Western blot analyses also failed to reveal changes in the levels of cystatins (saliva proteins that inhibit protease activity). Thus, increased cysteine protease activity appears to be directly related to submandibular acinar cell loss in NOD-scid mice involving the apoptotic pathway. Additional protease activity in saliva and gland lysates of older NOD and NOD-scid mice, apparently mutually distinct from cysteine proteases, generated an enzymatically cleaved parotid secretory protein. We suggest, therefore, that proteolytic enzyme activity contributes to loss of exocrine gland tolerance by generating abnormally processed protein constituents.


Subject(s)
Cysteine Endopeptidases/metabolism , Diabetes Mellitus, Type 1/enzymology , Saliva/enzymology , Sjogren's Syndrome/enzymology , Submandibular Gland/enzymology , Aging/metabolism , Animals , Apoptosis , Blotting, Western , Cystatins/analysis , Diabetes Mellitus, Type 1/genetics , Disease Models, Animal , Electrophoresis, Polyacrylamide Gel , Humans , Mice , Mice, Inbred BALB C , Mice, Inbred NOD , Mice, SCID , Prediabetic State/enzymology , Prediabetic State/genetics , Salivary Proteins and Peptides/analysis , Sjogren's Syndrome/genetics , Species Specificity , Submandibular Gland/growth & development
6.
Am J Physiol ; 272(4 Pt 1): G863-71, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9142919

ABSTRACT

Nonobese diabetic (NOD) mice, an animal model for type I autoimmune diabetes and autoimmune sialoadenitis, abnormally express parotid secretory protein (PSP) in the submandibular glands (Robinson, C. P., H. Yamamoto, A. B. Peck, and M. G. Humphreys-Beher. Clin. Immunol. Immunopathol. 79: 50-59, 1996). To evaluate possible PSP gene dysregulation in the NOD mouse, we have examined a number of organs and tissues for PSP mRNA transcripts and protein expression. Results indicate that PSP is produced in the lacrimal glands of NOD mice as well as most laboratory mouse strains. Although purified salivary PSP from C3H/HeJ or BALB/c mice fails to affect amylase enzyme activity in in vitro assays, PSP bound to whole bacteria in a Zn2+-dependent manner. Additionally, radiolabeled protein bound to specific bacterial membrane proteins using a ligand binding assay. PSP gene transcription, but not protein production, was observed in the heart and pancreas from NOD mice, indicating abnormal transcription of the PSP gene. Sequence analysis of PSP cDNA from NOD mice revealed numerous base differences (compared with the published PSP sequence) capable of leading to significant amino acid substitutions, suggestive of strain-specific differences for the protein in mice. Together these results suggest that there exists in the NOD mouse a dysregulation of PSP transcription in various tissues. However, except for C3H/HeJ mice, PSP appears as a normal product of the lacrimal glands where, as in saliva, it may function as a nonimmune antimicrobial agent in the protection of tissue surfaces exposed to the external environment.


Subject(s)
Adhesins, Bacterial/physiology , Exocrine Glands/metabolism , Lacrimal Apparatus/metabolism , Salivary Proteins and Peptides/metabolism , Salivary Proteins and Peptides/physiology , Amylases/metabolism , Animals , Bacteria/metabolism , Base Sequence , Blotting, Western , Female , Genes , Male , Membrane Proteins/metabolism , Mice , Mice, Inbred C3H/metabolism , Mice, Inbred NOD/genetics , Mice, Inbred NOD/metabolism , Mice, Inbred Strains , RNA, Messenger/metabolism , Salivary Proteins and Peptides/genetics
7.
J Exp Med ; 174(2): 459-66, 1991 Aug 01.
Article in English | MEDLINE | ID: mdl-1906922

ABSTRACT

It is not yet known what properties distinguish macrophages which can kill facultative intracellular bacteria, such as Listeria monocytogenes, from those which cannot. Listeria is an organism which requires iron for growth, yet macrophage listericidal mechanisms are also likely to be iron dependent. We show here that resident peritoneal macrophages and thioglycollate-elicited macrophages cannot kill listeria, but proteose peptone-elicited and FCS-elicited macrophages can. All these cell populations phagocytose listeria. Transferrin receptor expression is low on resident cells, intermediate on peptone- and FCS-elicited cells, and high on thioglycollate-elicited cells. Transferrin transports iron into cells via the transferrin receptor: thus, iron content of resident cells is low, of peptone- and FCS-elicited cells is intermediate, and of thioglycollate-elicited cells is high. Moreover, antibody to transferrin, which prevents it binding its receptor, inhibits listericidal macrophages from killing this bacterium. Finally, nonlistericidal cells with high transferrin receptor expression and high intracellular iron become listericidal if they are incubated with apotransferrin, an iron-free ligand which prevents iron uptake by cells. These data suggest that macrophages must have enough available intracellular iron to support listericidal mechanisms, but too much iron favors growth of the bacterium, which no longer can be killed by the macrophage.


Subject(s)
Iron/physiology , Listeria monocytogenes/immunology , Macrophages/immunology , Receptors, Transferrin/physiology , Transferrin/physiology , Animals , Mice , Mice, Inbred Strains , Peptones/administration & dosage , Peritoneal Cavity/cytology , Phagocytosis/physiology , Thioglycolates/administration & dosage
8.
J Gen Microbiol ; 136(6): 997-100, 1990 Jun.
Article in English | MEDLINE | ID: mdl-2117044

ABSTRACT

We demonstrate that cathepsin G, derived from human neutrophils, exhibits potent in vitro antimicrobial activity against Listeria monocytogenes. Cathepsin G listericidal activity was by a non-enzymic mechanism and was dependent on the cationic nature of the molecule. The listericidal activity of cathepsin G occurred in a manner that was both time-dependent and concentration-dependent.


Subject(s)
Cathepsins/pharmacology , Listeria monocytogenes/drug effects , Neutrophils/enzymology , Cathepsin G , Cations , Hot Temperature , Humans , Kinetics , Serine Endopeptidases
9.
Biochim Biophys Acta ; 930(1): 122-6, 1987 Aug 19.
Article in English | MEDLINE | ID: mdl-3040115

ABSTRACT

E-series prostaglandins have been shown to inhibit hepatic glucagon-stimulated glycogenolysis without inhibiting glycogenolysis stimulated by cAMP analogs. In the present studies, prostaglandin E2 and 16,16-dimethylprostaglandin E2 inhibited glucagon-stimulated cAMP accumulation in isolated rat hepatocytes by 25% and 46%, respectively, without affecting basal cAMP levels. Half-maximal inhibition of glucagon-stimulated cAMP accumulation occurred at approx. 10(-7) M 16,16-dimethylprostaglandin E2. 16,16-Dimethylprostaglandin E2 inhibited glucagon-stimulated palmitate oxidation in intact hepatocytes without affecting basal rates of palmitate oxidation. 16,16-Dimethylprostaglandin E2 had no effect on palmitate oxidation in a liver homogenate system. These studies demonstrate that prostaglandin E antagonizes the effects of glucagon on hepatic metabolism by inhibiting glucagon-stimulated cAMP accumulation.


Subject(s)
Cyclic AMP/biosynthesis , Fatty Acids/metabolism , Glucagon/antagonists & inhibitors , Liver/metabolism , Prostaglandins E/pharmacology , 16,16-Dimethylprostaglandin E2/pharmacology , Animals , Dinoprostone , Glucagon/pharmacology , Liver/drug effects , Male , Oxidation-Reduction , Palmitic Acid , Palmitic Acids/metabolism , Rats , Rats, Inbred Strains
SELECTION OF CITATIONS
SEARCH DETAIL
...